We are live on ! Find out more
ABBV icon

AbbVie

3,745 hedge funds and large institutions have $233B invested in AbbVie in 2024 Q4 according to their latest regulatory filings, with 442 funds opening new positions, 1,502 increasing their positions, 1,409 reducing their positions, and 131 closing their positions.

New
Increased
Maintained
Reduced
Closed

237% more first-time investments, than exits

New positions opened: 442 | Existing positions closed: 131

7% more funds holding

Funds holding: 3,4993,745 (+246)

7% more repeat investments, than reductions

Existing positions increased: 1,502 | Existing positions reduced: 1,409

6% more call options, than puts

Call options by funds: $3.18B | Put options by funds: $2.99B

0.4% more ownership

Funds ownership: 71.92%72.32% (+0.4%)

7% less capital invested

Capital invested by funds: $250B → $233B (-$16.8B)

20% less funds holding in top 10

Funds holding in top 10: 210167 (-43)

Holders
3,745
Holders Change
+246
Holders Change %
+7.03%
% of All Funds
49.32%
Holding in Top 10
167
Holding in Top 10 Change
-43
Holding in Top 10 Change %
-20.48%
% of All Funds
2.2%
New
442
Increased
1,502
Reduced
1,409
Closed
131
Calls
$3.18B
Puts
$2.99B
Net Calls
+$192M
Net Calls Change
-$583M
Name Holding Trade Value Shares
Change
Change in
Stake
SAM
451
Silvercrest Asset Management
New York
$22.3M -$4.09M -22,241 -15%
DP
452
DDD Partners
Washington
$22.3M +$2.05M +11,168 +10%
IAA
453
Independent Advisor Alliance
North Carolina
$22.2M +$1.56M +8,480 +7%
RPAM
454
Rhenman & Partners Asset Management
Sweden
$22.1M -$9.72M -52,850 -30%
PI
455
PineBridge Investments
New York
$22.1M -$37.6M -204,292 -62%
BPA
456
Beacon Pointe Advisors
California
$22M -$1.32M -7,157 -5%
AT
457
AMF Tjänstepension
Sweden
$21.9M +$14.5M +79,065 +178%
CSP
458
Cary Street Partners
Virginia
$21.9M +$22.6M +123,013 New
SF
459
Synovus Financial
Georgia
$21.7M -$1.39M -7,541 -6%
BT
460
Brandywine Trust
Delaware
$21.6M -$934K -5,080 -4%
KRS
461
Kentucky Retirement Systems
Kentucky
$21.6M -$307K -1,672 -1%
BCWM
462
Bartlett & Co Wealth Management
Ohio
$21.4M -$310K -1,684 -1%
GF
463
Gabelli Funds
New York
$21.3M -$3.33M -18,087 -13%
BGIM
464
Boussard & Gavaudan Investment Management
United Kingdom
$21.1M +$22.1M +120,000 New
ASN
465
Advisory Services Network
Georgia
$21.1M -$4.18M -22,730 -16%
FAB
466
First American Bank
Illinois
$21.1M +$151K +823 +0.7%
AIMC
467
Alley Investment Management Company
Illinois
$20.9M +$543K +2,951 +3%
VCM
468
Violich Capital Management
California
$20.8M -$30.2K -164 -0.1%
Lazard Asset Management
469
Lazard Asset Management
New York
$20.5M -$4.8M -26,115 -18%
RIA
470
Regal Investment Advisors
Michigan
$20.4M +$557K +3,032 +3%
TFGT
471
TS Financial Group (TSFG)
Illinois
$20.4M +$1.81M +9,866 +9%
WA
472
Waverly Advisors
Alabama
$20.3M +$2.83M +15,383 +16%
ACA
473
Aptus Capital Advisors
Alabama
$20.1M +$5.51M +29,972 +36%
CAG
474
Crestwood Advisors Group
Massachusetts
$20.1M +$424K +2,305 +2%
CFG
475
Citizens Financial Group
Rhode Island
$20M +$2.49M +13,542 +14%

ABBV Hedge Fund Activity: Q4 2024 in Review

3,745 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q4 2024, worth a combined $233B — down 6.7% from $250B a quarter earlier.

Buyers outnumbered sellers: 442 funds opened new ABBV positions and 131 closed out — a net gain of 311 holders — while 1,502 added to existing stakes and 1,409 trimmed.

The largest buyer was BlackRock, adding an estimated $1.11B. The largest seller was Capital International Investors, cutting an estimated $1.52B.

  • 3,745 institutional investors held AbbVie (ABBV) as of Q4 2024, up from 3,499 in Q3 2024.
  • Funds reported $233B of AbbVie stock for Q4 2024, down 6.7% quarter-over-quarter.
  • 442 funds opened new AbbVie positions in Q4 2024 and 131 closed out, a net change of +311 holders.
  • The largest AbbVie buyer in Q4 2024 was BlackRock, an estimated $1.11B added.
  • The largest AbbVie seller in Q4 2024 was Capital International Investors, an estimated $1.52B sold.

Based on aggregated 13F filings for Q4 2024.